Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (467)	6/16/2003 12:52:03 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 668

Curis Reports On BMP-7 Studies DOW JONES NEWSWIRES CAMBRIDGE, Mass. -- Curis Inc. (CRIS) said two studies demonstrated the potential of using BMP-7 as treatment to improve kidney function and prevent vascular disease associated with chronic progressive kidney disease. In a press release Monday, the drug development company said BMP-7, which was developed by Curis for various kidney and neurological related disorders, was licensed in November to Johnson & Johnson's (JNJ) Ortho Biotech Products L.P. The first study showed that treatment with BMP-7 improves kidney function in a diabetes-associated model of chronic kidney disease. The second study showed that BMP-7 treatment prevents the development of atherosclerosis, or blood vessel disease, in a model of chronic progressive kidney disease. As reported, Curis said it added $14 million to its cash position on Oct. 1, 2002, by selling future royalty rights for the BMP-7 osteogenic protein to Stryker Corp. (SYK). Shares of Curis closed Friday at $4.03, down 29 cents, or 6.7%, on volume of 1.62 million shares. Average daily volume is 1.07 million shares.